Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing (NCT05059522)
AVELUMAB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED AVELUMAB CLINICAL STUDIES.
🩺 Plain-English Summary (8th-Grade Level)
This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.
Who can join: Review the eligibility criteria below.
Location: Highlands Oncology Group, PA — Fayetteville, Arkansas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (71 Sites)
Showing the first 25 of 71 sites.
- Highlands Oncology Group, PA — Fayetteville, Arkansas
- Highlands Oncology Group, PA — Rogers, Arkansas
- Highlands Oncology Group, PA — Springdale, Arkansas
- The Regents of the University of California — Los Angeles, California
- UCLA Hematology/Oncology — Los Angeles, California
- Moffitt Cancer Center — Tampa, Florida
- MSK Basking Ridge — Basking Ridge, New Jersey
- MSK Monmouth — Middletown, New Jersey
- MSK Bergen — Montvale, New Jersey
- MSK Commack — Commack, New York
- MSK Westchester — Harrison, New York
- Memorial Sloan Kettering Cancer Center (IDS Pharmacy) — Long Island City, New York
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street). — New York, New York
- Memorial Sloan Kettering Cancer Center 53rd street. — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- MSK Nassau — Uniondale, New York
- Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania
- The Trustees of the University of Pennsylvania, Clinical Research (OCR) — Philadelphia, Pennsylvania
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- Fred Hutchinson Cancer Center — Seattle, Washington
- Macquarie University — North Ryde, New South Wales
- Mater Hospital Sydney — Wollstonecraft, New South Wales
- Melanoma Institute Australia — Wollstonecraft, New South Wales
- The Prince Charles Hospital — Chermside, Queensland
- UZ Gent — Ghent, Oost-vlaanderen
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Malignancies
- BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) — Duarte, California
- Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies — New York, New York
- An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers — Coral Gables, Florida
Explore by condition: All Advanced Malignancies clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.